AbbVie Reports meta-analysis Data for Idecabtagene vicleucel in Myasthenia gravis

AbbVie today announced meta-analysis results for idecabtagene vicleucel in patients with myasthenia gravis. The study demonstrated that idecabtagene vicleucel improves progression-free survival compared to standard of care or placebo. These results provide important insights into the treatment of myasthenia gravis and support the continued development of idecabtagene vicleucel in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.